A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers.
This study has been completed.
Study NCT00423566
Information provided by University of Oxford
First Received: January 17, 2007
No Changes Posted
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
